Health Highlights: Jan. 9, 201401/09/14
Here are some of the latest health and medical news
developments, compiled by the editors of HealthDay:
Officials Confirm First North American Death From H5N1 Bird
The first death in North America from H5N1 bird flu has been
reported in Alberta, Canada. The victim was a resident of the
province who had recently traveled to Beijing, China.
Health officials said there was no risk of transmission of the
virus between humans,
The patient first showed symptoms on a Dec. 27 flight from
Beijing to Vancouver. The person then spent a few hours in the
Vancouver airport before taking a flight to Edmonton.
The patient was admitted to hospital Jan. 1. The symptoms of
headache, fever and malaise worsened and the patient died Jan. 3.
The Public Health Agency of Canada was notified about the case Jan.
5, and the H5N1 infection was confirmed in a lab test Wednesday
Officials said they do not know how the patient was infected.
The patient did not leave Beijing, did not visit any markets and
did not travel to farms.
Woman to Give Birth to Own Granddaughter
A 58-year-old Utah woman is expected to give birth in early
February to her first grandchild.
Julia Navarro is carrying the baby for her daughter Lorena
McKinnon, who has had about a dozen miscarriages since she and her
husband began trying to have a baby three years ago, the
McKinnon, 32, and her husband began searching for a surrogate to
carry their baby. A friend and a sister considered it, but decided
against it. That's when Navarro offered to be the surrogate.
She underwent hormone shots for three months before a fertilized
embryo from her daughter and son-in-law could be implanted. Navarro
said she has had a smooth pregnancy carrying her granddaughter, the
New Diabetes Drug Approved by FDA
A new pill to treat adults with type 2 diabetes has been
approved by the U.S. Food and Drug Administration.
Farxiga (dapaglifozin) tablets were approved to improve
patients' blood sugar control, in combination with diet and
exercise. The approval is based on findings from 16 clinical trials
that included more than 9,400 people with type 2 diabetes.
An increased number of bladder cancers were diagnosed among
patients who took the drug, so it is not recommended for patients
with bladder cancer, the FDA said. The most common side effects
among patients who took Farxiga were genital fungal infections and
urinary tract infections.
The FDA ordered six post-approval studies for the drug. The
studies will examine things such as cardiovascular and bladder
cancer risk, liver problems, and pregnancy outcomes among patients
taking the drug. Two studies will assess the use of the drug in
Farxiga is marketed by Bristol-Meyers Squibb Company and
Copyright © 2014
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.